Shanghai Chest Hospital
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1957-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
167
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (132 trials with phase data)• Click on a phase to view related trials
A Study of QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in Patients With Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy
- Conditions
- Limited-stage Small Cell Lung Cancer (LS-SCLC)ChemoradiotherapyInduction TherapyConsolidation Immunotherapy
- Interventions
- First Posted Date
- 2025-07-29
- Last Posted Date
- 2025-07-29
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT07091305
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）
- Conditions
- OligoProgressive Metastatic DiseaseNon-Small Cell Lung Cancer
- Interventions
- Procedure: Radiotherapy or SurgeryDrug: Standard Medical Therapy
- First Posted Date
- 2025-07-22
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 97
- Registration Number
- NCT07076693
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Recruiting, Shanghai, China
A Study of Contrast-enhanced EBUS in Lung Lesions and Intrathoracic Lymph Nodes
- Conditions
- Lung LesionsMediastinal and Hilar Lymph Node Enlargement
- First Posted Date
- 2025-07-11
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT07060378
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
- Conditions
- Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Drug: Osimertinib-based adaptive treatment
- First Posted Date
- 2025-07-10
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT07058519
- Locations
- 🇨🇳
Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China
Optical Biopsy and Cytological Evaluation for Intrathoracic Lymphadenopathy
- Conditions
- Intrathoracic Lymphadenopathy
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT07047417
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 34
- Next
News
Everest Medicines Advances AI-Powered mRNA Platform with Cancer Vaccine Breakthroughs
Everest Medicines unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day, showcasing a fully integrated system spanning antigen design to manufacturing.
Chinese Drug Combination Outperforms Keytruda in Advanced Lung Cancer Trial
A Chinese-developed drug combination of Benmelstobart and Anlotinib demonstrated superior efficacy over pembrolizumab (Keytruda) in treating PD-L1-positive advanced non-small cell lung cancer patients.
Shanghai Chest Hospital to Initiate CAR-T Therapy Trial for Lung Cancer
Shanghai Chest Hospital will begin a clinical trial in January to assess a novel CAR-T cell therapy for lung cancer, aiming to enroll 20 patients in the first phase.